Gilead Sciences Inc buy stratec
Summary
This prediction ended on 20.12.19 with a price of €59.38. The price of Gilead Sciences Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -17.39%. Dividends of €4.50 are taken into consideration when calculating the performance. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Gilead Sciences Inc | -2.107% | -2.107% | -22.007% | 12.435% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by stratec for this prediction
In the thread Gilead Sciences Inc diskutieren
Gilead has a great track record of strong free cash flow...
Regardless of the economy, patients with critical illnesses, such as HIV/AIDS, can't afford to stop receiving treatments. For example, there are over a million HIV-positive people in the U.S. and almost 40 million in total globally (and the numbers continue to grow). With proper drugs they can live longer, and the earlier they receive treatment, the better. As a global leading player in this field, Gilead Sciences is grabbing a big share of the expanding market for HIV/AIDS drugs and would continue doing so even when the next recession hits. Gilead Science has also been working to widen its focus to cover other critical illnesses, such as liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory diseases.
With operations in over 30 countries, Gilead Sciences has a great track record of strong free cash flow and high efficiency in capital allocation throughout various periods of an economic cycle. During the financial crisis, the company beat analysts' estimates and raised guidance, increasing annual revenue from $4,230 million in 2007 to $7,011 million in 2009 and free cash flow from $1,687 million in 2007
to $2,850 million in 2009, while being able to keep ROIC at around 40% and ROE above 50%.
stratec stimmt am 14.01.2018 der Outperform-
der institutionellen Analysten aber mit dem Kursziel 95$ zu.
Gute Idee!
Stopped prediction by stratec for Gilead Sciences Inc
Gilead Sciences Inc
24.04.20
04.11.21
05.11.21
Gilead Sciences Inc
20.12.19
23.04.20
23.04.20